

**AT A GLANCE**

*Technology*

Precise, selective protein optimization

*Focus*

Development of first-in-class & best-in-class protein drugs

Improving efficacy, safety & ease of use

*Speed*

Research program launch to clinic in less than 3 years

*Experience*

Executives with experience in bringing protein drugs to market

80 high caliber employees

**MANAGEMENT**

- Stephen W. Kaldor, PhD  
*President & CEO*
- Douglas Axelrod, MD, PhD  
*Chief Medical Officer & SVP, Development*
- Ho Sung Cho, PhD  
*Chief Technology Officer*
- Cris Calsada  
*VP, Finance*
- Kevin Eastwood  
*VP, Corporate Development*
- John Wallen III, PhD, JD  
*VP, Intellectual Property & Corporate Legal*

**COMPANY OVERVIEW**

Ambrx Inc. is a clinical stage biopharmaceutical company with a broad biologics platform that allows it to create best-in-class protein therapeutics, including improved versions of native proteins and therapeutic antibodies. Its most advanced product candidate, ARX201, is a long-acting human growth hormone (hGH) drug candidate currently in phase II clinical trials. Ambrx is collaborating on the development and commercialization of ARX201 with EMD Serono, the US Affiliate of Merck Serono. In 2009, Ambrx announced a multi-target alliance with Pfizer as well as an expansion of the collaboration with EMD Serono to include ARX424 for Multiple Sclerosis. Ambrx has further validated its biologics platform through substantial partnerships with Eli Lilly & Co. and Merck & Co. Ambrx is advancing a robust portfolio of products including antibodies, spanning multiple therapeutic areas that are highly optimized for efficacy,

**MARKET**


Worldwide protein drug sales are currently estimated to be more than \$80 billion per year, and are expected to reach \$125 billion by the year 2015. The protein pharmaceutical market is driven increasingly by the development of next-generation proteins.

*Source: Decision Resources 2009*

**PIPELINE**

Ambrx has a number of products at various stages of development in its pipeline, with a focus on best-in-class product opportunities. The company's lead program, ARX201, is a long-acting human growth hormone that is currently in clinical trials. ARX201 is administered once weekly, a notable improvement over current once-daily hGH therapies. Ambrx has multiple other protein and antibody product candidates that target a variety of diseases such as cancer, diabetes, CNS disorders and obesity all advancing towards the clinic.

**Current Ambrx Pipeline**



**Broad Portfolio of Clinical and Pre-clinical Phase Assets**



## BOARD OF DIRECTORS


- **John Diekman, PhD**  
*Chairman, Managing Director, 5AM Ventures*
- **Richard DiMarchi, PhD**  
*Retired Group Vice President, Lilly Research Labs, Ambrx co-founder*
- **Shehan Dissanayake, PhD**  
*CEO, Tavistock Life Sciences*
- **Stephen W. Kaldor, PhD**  
*President, Chief Executive Officer, Ambrx*
- **Allan Marchington, PhD**  
*General Partner, Apposite Capital, LLP*
- **Peter Schultz, PhD**  
*Professor, The Scripps Research Institute; Institute Director, GNF, Ambrx co-founder*
- **David Singer**  
*Principal, Maverick Capital, Ltd.*

## INVESTORS

- 5AM Ventures
- Apposite Capital, LLP
- Glynn Ventures
- Maverick Capital, Ltd.
- Merck Serono
- Roche Venture Fund
- Scottish Widows Investment Partnership
- Tavistock Life Sciences
- Versant Ventures


Revised 9/22/2009

## TECHNOLOGY



Ambrx's patented core technologies, ReCODE™ and EuCODE™, are based on protein medicinal chemistry. Both ReCODE™ and EuCODE™ allow for the *precise, site-selective* substitution of novel Ambrx amino acids at any site within a protein. The novel amino acid serves as a specific target for coupling molecules to a protein. The specific site of attachment impacts pharmacology, potency and the therapeutic window of drug candidates. By analyzing a number of site-specific protein variants, Ambrx can rapidly select the molecule with the best overall profile for further evaluation as a drug candidate. This technology can also be used more broadly to specifically couple a diverse array of molecules to a protein, creating a wide array of novel protein-based products.

### Diverse Conjugation Opportunities Allow a Wide Array of Product Candidates



## BUSINESS AND COMMERCIAL STRATEGY

With this unique approach for the optimization of protein based therapeutics, Ambrx has the potential to create best-in-class follow-on product candidates for established markets and improve the drug-like properties of protein based therapeutics in emerging markets. ReCODE™ and EuCODE™ are supported by an extensive intellectual property portfolio of over 600 patents and patent applications, including issued, broad enabling patents. Ambrx has applied ReCODE™ and EuCODE™ successfully in multiple projects, creating differentiated product candidates for Ambrx and its partners.

## PARTNERING WITH AMBRX

Ambrx is seeking collaborations with pharmaceutical and biotech companies interested in leveraging its technologies. Contact: Kevin Eastwood at [kevin.eastwood@ambrx.com](mailto:kevin.eastwood@ambrx.com)